Final phase 3 MATTERHORN data position perioperative durvalumab plus FLOT as a new standard in resectable gastric or gastroesophageal junction adenocarcinoma.
|Videos|February 8, 2019
Using Genetics to Determine Disparities in Gastric Cancer
Author(s)Shaila Merchant, MD
Cancer Network spoke with Dr. Shaila Merchant about the difficulty in determining and linking the many disparities in gastric cancer and how genetic research can help.
Advertisement
Cancer Network spoke with Dr. Shaila Merchant about the difficulty in determining and linking the many disparities in gastric cancer and how genetic research can help.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5